F.D.A. Approves Ozempic to Treat Kidney Diseasenews2025-01-28T21:00:58+00:00January 28th, 2025|The New York Times|
Insulin Prices Dropped. But Some Poor Patients Are Paying More.news2025-01-16T10:00:13+00:00January 16th, 2025|The New York Times|
Pfizer Stopped Us From Getting Ozempic Decades Agonews2024-12-25T23:11:22+00:00December 25th, 2024|The New York Times|
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.news2024-12-19T10:00:46+00:00December 19th, 2024|The New York Times|
Long a ‘Crown Jewel’ of Government, N.I.H. Is Now a Targetnews2024-12-02T01:11:12+00:00December 2nd, 2024|The New York Times|
Ozempic Could Prevent Diabetes. Should We Use It For That?news2024-11-13T23:00:30+00:00November 13th, 2024|The New York Times|
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Saysnews2024-10-03T16:50:39+00:00October 3rd, 2024|The New York Times|
Is Obesity a Disease? It’s Complicated in the Age of Ozempic.news2024-09-19T10:55:46+00:00September 19th, 2024|The New York Times|
Eli Lilly’s Popular Weight Loss Drug, Zepbound, Is Getting a Price Cutnews2024-08-27T10:45:07+00:00August 27th, 2024|The New York Times|